C. Difficile
Lyon, France and Swiftwater, Pa. — Sanofi Pasteur announced Dec. 15 that it is expanding its phase II clinical study of a vaccine against Clostridium difficile infection into the United States.
Browse by Category
Browse by Location
Search
Tag Cloud
H1N1 National Institutes of Health Human papillomavirus Harvard School of Public Health FDA Influenza Emergency preparedness MRSA anthrax Bio-Rescue Gates Foundation research grants immunization AIDS CDC MIND Institute mercury autism Health Canada HHS Infectious disease Measles Tuberculosis Malaria smallpox research pneumonia NIAID NIFA Defense Dept Streptococcus kala azar food safety Dengue fever Cancer typhoid E. coli hepatits polio Ebola dna technology antibiotics Mumps Alzheimer's Yellow Fever pneumococcal disease HIB Pertussis Tetanus diptheria prevention Bioweapons Avian flu rotavirus Reaction Shingles tracking Detection technology Travelers’ Diarrhea gum disease C difficile jaundice meningitis nasal vaccine HSV2 Chlamydia needle-free foot and mouth disease leukemia chicken pox cervical cancer rsv Staphylococcus aureus scarification Helicobacter cholera Prostate Cancer salmonella Rubella chikungunya virus SV40 smoking tropical diseases whooping cough SARS ragweed pancreatic cancer retrovirus rheumatoid arthritis H5N1 Pharmaceuticals vitamins
Subscribe to our newsletter
RSS Feed
